ASX - By Stock
|
RCP |
Re:
Ann: Capital Raising Investor Presentation
|
|
bubsmark
|
46 |
6.2K |
0 |
14:55 |
14:55 |
ASX - By Stock
|
46
|
6.2K
|
0
|
|
ASX - By Stock
|
TI1 |
Re:
Watcher closely
|
|
bubsmark
|
97 |
28K |
0 |
14:06 |
14:06 |
ASX - By Stock
|
97
|
28K
|
0
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
bubsmark
|
28K |
16M |
9 |
08:20 |
08:20 |
ASX - By Stock
|
28K
|
16M
|
9
|
|
ASX - By Stock
|
LTR |
Re:
Ann: Appendix 3Y - Tim Goyder
|
|
bubsmark
|
38 |
8.7K |
7 |
25/02/21 |
25/02/21 |
ASX - By Stock
|
38
|
8.7K
|
7
|
|
ASX - By Stock
|
KFE |
Re:
Pump and dump March 2021
|
|
bubsmark
|
61 |
11K |
3 |
24/02/21 |
24/02/21 |
ASX - By Stock
|
61
|
11K
|
3
|
|
ASX - By Stock
|
ADO |
Re:
ADO Price Prediction
|
|
bubsmark
|
409 |
103K |
4 |
24/02/21 |
24/02/21 |
ASX - By Stock
|
409
|
103K
|
4
|
|
ASX - By Stock
|
RCP |
Re:
Ann: Trading Halt
|
|
bubsmark
|
25 |
4.6K |
0 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
25
|
4.6K
|
0
|
|
ASX - By Stock
|
OZL |
Re:
Copper on the move
|
|
bubsmark
|
40 |
9.6K |
0 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
40
|
9.6K
|
0
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
bubsmark
|
28K |
16M |
4 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
28K
|
16M
|
4
|
|
ASX - By Stock
|
WFL |
Re:
Ann: Notice under Section 708A(5) of the Corporations Act
|
|
bubsmark
|
4 |
885 |
1 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
4
|
885
|
1
|
|
ASX - By Stock
|
PNV |
Re:
Ann: H1 FY21 Results Investor Presentation
|
|
bubsmark
|
128 |
27K |
2 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
128
|
27K
|
2
|
|
ASX - By Stock
|
PNV |
Re:
Ann: H1 FY21 Results Investor Presentation
|
|
bubsmark
|
128 |
27K |
5 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
128
|
27K
|
5
|
|
ASX - By Stock
|
ADO |
Re:
ADO Price Prediction
|
|
bubsmark
|
409 |
103K |
4 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
409
|
103K
|
4
|
|
ASX - By Stock
|
ADO |
Re:
ADO Price Prediction
|
|
bubsmark
|
409 |
103K |
5 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
409
|
103K
|
5
|
|
ASX - By Stock
|
ADO Biotech |
Re:
EU moving to standardise COVID rapid antigen testing
|
|
bubsmark
|
14 |
3.6K |
6 |
19/02/21 |
19/02/21 |
ASX - By Stock
|
14
|
3.6K
|
6
|
|
ASX - By Stock
|
FEX |
Re:
Ann: Update on maiden shipment of Iron Ridge product
|
|
bubsmark
|
253 |
42K |
3 |
19/02/21 |
19/02/21 |
ASX - By Stock
|
253
|
42K
|
3
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
bubsmark
|
28K |
16M |
6 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
28K
|
16M
|
6
|
|
ASX - By Stock
|
FMG |
Re:
FMG - 2021 Interim Dividend
|
|
bubsmark
|
504 |
203K |
8 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
504
|
203K
|
8
|
|
ASX - By Stock
|
ADO |
Re:
Ann: AnteoTech Progresses COVID-19 Test Toward Market Launch
|
|
bubsmark
|
935 |
207K |
3 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
935
|
207K
|
3
|
|
ASX - By Stock
|
FEX |
Re:
Ann: Update on maiden shipment of Iron Ridge product
|
|
bubsmark
|
253 |
42K |
3 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
253
|
42K
|
3
|
|
ASX - By Stock
|
FMG |
Re:
FMG - 2021 Interim Dividend
|
|
bubsmark
|
504 |
203K |
2 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
504
|
203K
|
2
|
|
ASX - By Stock
|
FEX |
Re:
Ann: Update on maiden shipment of Iron Ridge product
|
|
bubsmark
|
253 |
42K |
1 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
253
|
42K
|
1
|
|
ASX - By Stock
|
OZL |
Re:
how many Oxiana holders
|
|
bubsmark
|
17 |
3.0K |
1 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
17
|
3.0K
|
1
|
|
ASX - By Stock
|
FMG |
Re:
FMG - 2021 Interim Dividend
|
|
bubsmark
|
504 |
203K |
5 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
504
|
203K
|
5
|
|
ASX - By Stock
|
PME |
Re:
Ann: Appendix 4D
|
|
bubsmark
|
4 |
453 |
1 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
4
|
453
|
1
|
|
ASX - By Stock
|
FEX |
Re:
Ann: Update on maiden shipment of Iron Ridge product
|
|
bubsmark
|
253 |
42K |
3 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
253
|
42K
|
3
|
|
ASX - By Stock
|
IOU |
Re:
Ann: Trading Halt
|
|
bubsmark
|
457 |
141K |
3 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
457
|
141K
|
3
|
|
ASX - By Stock
|
FMG |
Re:
Ann: Fortescue Leadership Changes
|
|
bubsmark
|
169 |
60K |
4 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
169
|
60K
|
4
|
|
ASX - By Stock
|
FMG |
Re:
Ann: Fortescue Leadership Changes
|
|
bubsmark
|
169 |
60K |
9 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
169
|
60K
|
9
|
|
ASX - By Stock
|
FMG |
Re:
Ann: Fortescue Leadership Changes
|
|
bubsmark
|
169 |
60K |
4 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
169
|
60K
|
4
|
|
ASX - By Stock
|
FMG |
Re:
Ann: Fortescue Leadership Changes
|
|
bubsmark
|
169 |
60K |
5 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
169
|
60K
|
5
|
|
ASX - By Stock
|
FMG |
Re:
Ann: Fortescue Leadership Changes
|
|
bubsmark
|
169 |
60K |
3 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
169
|
60K
|
3
|
|
ASX - By Stock
|
FMG |
Re:
Ann: Fortescue Leadership Changes
|
|
bubsmark
|
169 |
60K |
3 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
169
|
60K
|
3
|
|
ASX - By Stock
|
FMG |
Re:
Ann: Fortescue Leadership Changes
|
|
bubsmark
|
169 |
60K |
1 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
169
|
60K
|
1
|
|
ASX - By Stock
|
FMG |
Re:
Ann: Fortescue Leadership Changes
|
|
bubsmark
|
169 |
60K |
1 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
169
|
60K
|
1
|
|
ASX - By Stock
|
SUD |
Re:
Ann: Zelira Therapeutics Feasibility Study Update
|
|
bubsmark
|
33 |
5.1K |
8 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
33
|
5.1K
|
8
|
|
ASX - By Stock
|
IOU |
Re:
$1 Club
|
|
bubsmark
|
14K |
3.3M |
1 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
14K
|
3.3M
|
1
|
|
ASX - By Stock
|
NEA |
Re:
Ann: Half Yearly Report and Accounts
|
|
bubsmark
|
60 |
15K |
1 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
60
|
15K
|
1
|
|
ASX - By Stock
|
ADO |
Re:
ADO Price Prediction
|
|
bubsmark
|
409 |
103K |
3 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
409
|
103K
|
3
|
|
ASX - By Stock
|
FMG |
Re:
Brazil, Vale and other stories
|
|
bubsmark
|
46 |
16K |
1 |
13/02/21 |
13/02/21 |
ASX - By Stock
|
46
|
16K
|
1
|
|
ASX - By Stock
|
ADO |
Re:
ADO Charting and Technical Analysis
|
|
bubsmark
|
758 |
179K |
4 |
13/02/21 |
13/02/21 |
ASX - By Stock
|
758
|
179K
|
4
|
|
ASX - By Stock
|
FMG |
Re:
Brazil, Vale and other stories
|
|
bubsmark
|
46 |
16K |
1 |
13/02/21 |
13/02/21 |
ASX - By Stock
|
46
|
16K
|
1
|
|
ASX - By Stock
|
ADO |
Re:
DT interview 11th Feb
|
|
bubsmark
|
74 |
18K |
33 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
74
|
18K
|
33
|
|
ASX - By Stock
|
ADO |
Re:
DT interview 11th Feb
|
|
bubsmark
|
74 |
18K |
0 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
74
|
18K
|
0
|
|
ASX - By Stock
|
LTR |
Re:
Ann: Significant new gold-copper assays from drilling at Moora
|
|
bubsmark
|
215 |
59K |
17 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
215
|
59K
|
17
|
|
ASX - By Stock
|
ADO |
Re:
DT interview 11th Feb
|
|
bubsmark
|
74 |
18K |
3 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
74
|
18K
|
3
|
|
ASX - By Stock
|
ADO |
Re:
DT interview 11th Feb
|
|
bubsmark
|
74 |
18K |
21 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
74
|
18K
|
21
|
|
ASX - By Stock
|
ADO |
Re:
ADO Article in Daily Telegraph & Herald Sun 9/2/2021
|
|
bubsmark
|
126 |
32K |
1 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
126
|
32K
|
1
|
|
ASX - By Stock
|
ADO |
Re:
ADO Article in Daily Telegraph & Herald Sun 9/2/2021
|
|
bubsmark
|
126 |
32K |
2 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
126
|
32K
|
2
|
|
ASX - By Stock
|
CIM |
Re:
Ann: FY20 STATUTORY NPAT $620M, REVENUE $11.4B, NET CASH $190M
|
|
bubsmark
|
37 |
14K |
3 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
37
|
14K
|
3
|
|